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Abstract 20 
We previously reported a naturally occurring BF intersubtype recombinant Vpu variant with 21 
augmented capacity to enhance viral replication. Structural analysis of this variant revealed that 22 
its transmembrane domain (TMD) and α-helix I in the cytoplasmic domain (CTD) 23 
corresponded to subtype B, whereas CTD α-helix II corresponded to subtype F1. +HUHZH 24 
aimed at evaluating the role of Vpu CTD α-helix II domain on viral release enhancement        25    
and down-modulation of BST-2 and CD4 from cell surface. In addition, as serine residues in 26 
either Vpu amino acid positions 61 or 64 have been shown to regulate Vpu intracellular half-27 
life, which in turn could influence the magnitude of viral release, we also studied the impact of 28 
these residues in the VpuBF functions, since S61 and S64 are infrequently found among BF  29 
recombinant Vpu variants. Our results showed that interchange of Vpu α-helix II between 30 
subtypes (B→F) directly correlated with enhancement of viral release and, to a lesser extent, 31 
with changes in the capacity to down-modulate BST-2 and CD4 of the resulting chimera. No 32 
differences on viral release and BST-2 down-modulation were observed between                  33 
VpuBF and VpuBF-E61S. On the other hand, VpuBF-A64S showed a slightly reduced    34 
capacity to enhance viral production but was modestly more efficient than VpuBF in down-35 
modulating BST-2. In summary, our observations clearly evidence that α-helix II is actively 36 
involved in Vpu viral release-promoting activity, and that intersubtype recombination between 37 
subtypes B and F1 originated a protein variant with higher potential to boost the spread of the 38 
recombinant strain that harbors it. 39 
 40 
 41 
 42 
 43 
 44 
 45 
Introduction  46 
The viral protein U (Vpu), encoded in the HIV-1 genome (Cohen et al., 1988; Strebel et al., 47 
1988), is a type I transmembrane protein consisting of a short N-terminal domain, a single 48 
transmembrane α-helix domain, two cytosolic α-helices separated by a flexible connector 49 
loop, and a short C-terminal tail. This protein is known for performing two important 50 
functions during HIV-1 infection of target cells: a) it mediates the proteasomal degradation of 51 
newly synthesized CD4 receptor in the endoplasmic reticulum (Magadan et al., 2010; 52 
Margottin et al., 1998), and b) it enhances the release of virions from infected cells by 53 
antagonizing the restriction imposed by BST-2 (CD317/HM1.24/tetherin), an INFα-inducible 54 
host restriction factor (Neil et al., 2008; Van Damme et al., 2008). In addition, it has been 55 
recently demonstrated that SLAMF6/NTB-A, a transmembrane protein that induces natural 56 
killer cell-mediated killing of infected cells, is also down-regulated by Vpu from the plasma 57 
membrane (Shah et al., 2010).  58 
Early reports suggested that different Vpu domains were directing separate functions, 59 
identifying its cytoplasmic domain (CTD) as critical for CD4 degradation, and the 60 
transmembrane domain (TMD) as involved in promotion of viral release (Schubert et al., 61 
1996a; Schubert et al., 1996b; Schubert et al., 1994); however, recent studies demonstrated 62 
that discrete regions in both CTD and TMD are required to carry out its main functions 63 
(Magadan et al., 2010; Mangeat et al., 2009; Nomaguchi et al., 2010; Petit et al.2011). 64 
We recently reported a naturally occurring BF intersubtype recombinant Vpu with improved 65 
in vitro capacity to enhance viral replication when compared to a subtype B variant. The 66 
analysis of numerous BF intersubtype recombinant Vpu sequences revealed a highly 67 
conserved recombination pattern, similar to that observed in the prototypic BF recombinant 68 
strain CRF12_BF, in which the membrane-spanning and α-helix I domains correspond to 69 
subtype B, and the α-helix II to subtype F1 (De Candia et al., 2010). This pattern displays a 70 
breakpoint in a flexible and highly conserved amino acid sequence located between α-helix I 71 
and II. This region contains two critical serine residues (S52 and S56) which phosphorylation 72 
by casein kinase II (CK-II) is crucial for proteasome-mediated CD4 degradation (Magadan et 73 
al., 2010; Margottin et al., 1998) and for the control of BST-2 intracellular trafficking and/or 74 
degradation (Douglas et al., 2009; Goffinet et al., 2009; Goffinet et al., 2010; Mangeat et al., 75 
2009; Mitchell et al., 2009; Miyagi et al., 2009; Schmidt et al., 2011; Tervo et al., 2011).  76 
On the other hand, according to an early report by Estrabaud et al, Vpu degradation is a 77 
proteasome-mediated process that involves phosphorylation of a serine residue, either at 78 
positions 61 or 64 (S61 or S64), that triggers Vpu degradation by a not well elucidated β-79 
TrCP-independent pathway (Estrabaud et al., 2007). Replacement of S61 with alanine 80 
correlated with a marked increase in the protein half-life and, consequently, with the 81 
enhancement of viral release. This mutation did not affect CD4 degradation (Estrabaud et al., 82 
2007; Hill et al., 2010). We found that S61 is absent in the CRF12_BF Vpu sequence and in 83 
most of the related BF recombinant sequences, and that only 6.6% of them have a serine 84 
residue at position 64 (De Candia et al., 2010). 85 
Taking all this evidence into account, the present work was aimed at evaluating the 86 
contribution of α-helix-II in Vpu CTD and the impact of serine residues at positions 61 or 64, 87 
on viral release promotion and BST-2 and CD4 down-modulation capacity, in order to clarify 88 
the relationship between the structural and functional variations observed in the BF 89 
recombinant Vpu. 90 
  91 
Results 92 
 93 
BF Vpu’s α-helix II determines an increase in viral release in Vpu-dependent cell line 94 
models 95 
To evaluate the role of the α-helix II in viral release and to assess  the potential consequences 96 
of recombination involving this Vpu domain on it functions, two different recombinant Vpu 97 
variants were generated: i) VpuBF/B, where α-helix-II from a CRF12_BF-like variant was 98 
replaced with the α-helix-II from the NL4-3 reference strain, and ii) VpuB/F1, where α-helix-99 
II from NL4-3 was replaced with the α-helix-II from the CRF12_BF-like variant (Fig. 1a,b). 100 
To evaluate the protein expression levels, the cloning strategy used included the incorporation 101 
of a 6xHis-tag at the C-terminus of each recombinant protein variant. SDS-PAGE and 102 
Western blot analysis, as described in the Methods section, showed that all Vpu variants were 103 
expressed at similar levels (Fig. 2). These proteins were fully functional regarding the Vpu 104 
canonical activities. 105 
HeLa cells were used as a Vpu-dependent model to evaluate viral production. As described in 106 
the Methods section, pNL4-3 U35 and each of the Vpu expression vectors pCG-VpuB, pCG-107 
VpuF1, pCG-VpuBF, pCG-Vpu B/F1 and pCG-Vpu BF/B, were used to separately co-108 
transfect HeLa cell cultures. Co-transfection with the empty pCG vector was used as a 109 
negative control. Forty eight hours post-transfection, viral production was monitored by 110 
quantifying p24 antigen in cell culture supernatants. Similar transfection efficiency was 111 
achieved in all cases, as determined by the percentage of GFP-positive cells evaluated by 112 
FACS (data not shown).  113 
As depicted in Fig. 3 (a), transfection with VpuBF expression vector resulted in an 114 
approximately 2-fold increase in p24 production when compared to VpuB, which is in line 115 
with our previous observations (De Candia et al., 2010). Interestingly, VpuB/F1 was more 116 
efficient in promoting viral release than both VpuB and VpuF1 (p>0.01). Of note, viral 117 
production measured in VpuBF/B was lower than that associated to the naturally occurring 118 
VpuBF (p>0.01), resembling the VpuB biological behaviour. In this regard, no statistical 119 
differences were observed in p24 production among Vpu BF/B vs. VpuB, or VpuBF vs. Vpu 120 
B/F1. VpuF1 p24 production was slightly but significantly higher than VpuB (p<0.01) and 121 
significantly lower than VpuBF (p<0.01). 122 
These results clearly point out that, in our intersubtype recombination study model, Vpu α-123 
helix II is involved in the viral release promotion function of Vpu.  124 
 125 
A64S mutation in BF intersubtype recombinant Vpu affects viral release 126 
Phosphorylation of serine residues by a protein kinase is a process known to induce functional 127 
changes in a target protein or to regulate protein’s fate (Ciesla et al., 2011; Johnson & 128 
Barford, 1993; Tarrant & Cole, 2009). As stated above, phosphorylation of serine residues at 129 
positions 52 and 56 (S52, S56) in HIV-1 Vpu protein regulates its BST-2 and CD4 down-130 
modulation capacity, while phosphorylation of serine residues either at positions 61 or 64 131 
(S61 or S64) has been found to influence the protein half-life (Estrabaud et al., 2007). As 132 
shown in Fig. 1 (a), reference strain NL4-3 Vpu has a serine residue at position 61 (S61) and a 133 
valine residue at position 64 (A64), while BF intersubtype recombinant Vpu has a glutamic 134 
residue at position 61 (E61) and an alanine residue at position 64 (A64). 135 
To test the hypothesis that absence of  S61 and/or S64 in the BF recombinant Vpu could 136 
contribute to increase its capacity to promote viral production, mutant Vpu variants, in which 137 
amino acids at positions 61 or 64 were replaced with serine residues, (pCG-VpuBF E61S and 138 
pCG-VpuBF A64S) (Fig. 1a) were generated. VpuB expression vectors in which S61A and 139 
V64S mutations were introduced (pCG-VpuB S61A, pCG-VpuB V64S) were included as 140 
controls in the study. 141 
The impact of these changes in p24 production was evaluated by performing Hela cell co-142 
transfections and p24 quantitation as described above. We evaluated the protein expression 143 
level of each construct by Western blot (Fig. 2). No significant differences in p24 production 144 
were observed among VpuBF or VpuBF E61S. However, VpuBF A64S viral production was 145 
slightly but significantly lower than viral production for VpuBF (p<0.01)(Fig. 3b).  146 
Different results were obtained for VpuB; in line with those reported by Estrabaud et al 147 
(Estrabaud et al., 2007), replacement of S61 with alanine (VpuB S61A) was associated to a 148 
significant increase in p24 production when compared to the wild type protein (VpuB), 149 
confirming the contribution of S61 in the viral enhancement function of this particular (NL4-150 
3) viral strain. When S61 was absent and the valine residue at position 64 was replaced with a 151 
serine residue (VpuB V64S) no significant difference in p24 production was observed. 152 
 153 
Pure subtype, chimeric and serine-mutant Vpu variants have different capacities to 154 
down-modulate BST-2 155 
To determine the relative capacity of pure subtype, chimeric and serine-mutant Vpu variants 156 
to down-modulate BST-2 from cell surface, HeLa cell cultures were transfected with each 157 
Vpu-GFP expression vector as described above. Transfection with pCG-GFP empty vector 158 
was used as negative control. Transfection efficiency, assessed as percentage of GFP-positive 159 
cells, was similar in all cases (data not shown). 160 
Forty eight hours post-transfection, BST-2 cell surface expression was assessed by FACS and 161 
expressed as mean fluorescence intensity (MFI) (Fig. 4).   162 
All the variants studied retained their capacity to down-modulate BST-2 from cell surface. As 163 
shown in Fig. 4 (a), VpuBF was more efficient in modulating BST-2 when compared with 164 
VpuB and VpuF (p<0.01). Among the variants studied, VpuF was clearly the least efficient in 165 
down-modulating BST-2. No significant differences were observed when comparing VpuBF 166 
and VpuB/F1 or VpuB and VpuBF/B. Remarkably, Vpu BF and Vpu B/F1 variants were 167 
more efficient in modulating BST-2 than Vpu BF/B and VpuB respectively, indicating that α-168 
helix II is also implicated in Vpu-dependent BST-2 cell surface down-modulation. 169 
Nevertheless, viral release and BTS-2 cell surface expression observed for the BF 170 
recombinant variants did not show any direct correlation.  171 
As for the role of serine residues on BST-2 expression (Fig. 4b), no statistically significant 172 
differences were observed between VpuB and VpuB S61A or VpuBF and VpuBF E61S. 173 
Interestingly, VpuBF A64S showed a slightly lower capacity to down-modulate BST-2 from 174 
cell surface than VpuBF (p <0.01).  175 
 176 
Pure subtype and chimeric Vpu have different capacities to down-modulate CD4 177 
expression 178 
We subsequently examined and compared the ability of pure subtype, chimeric and serine-179 
mutant Vpu variants to induce the down-modulation of CD4 from the cell surface. HeLa T4 180 
cells were transfected separately with each Vpu-GFP expression vector. Transfection with 181 
pCG-GFP empty vector was used as negative control.  182 
Forty eight hour post-transfection, CD4 cell surface expression in Vpu-expressing cells was 183 
evaluated by FACS, and expressed as MFI. Similar transfection efficiency, determined as 184 
percentage of GFP-positive cells by FACS, was obtained in all cases (data not shown). 185 
All Vpu variants efficiently reduce CD4 cell surface expression when compared to empty 186 
vector (Fig. 5). As shown in Fig. 5 (a), VpuF1, VpuBF and Vpu B/F1 were more efficient in 187 
down-modulating CD4 from the cell surface than VpuB (p <0.01). No statistically significant 188 
differences were observed between VpuBF and VpuB/F1, or between VpuB and VpuBF/B. 189 
Regarding the role of the serine residue at positions 61 and 64 on CD4 cell surface expression, 190 
no statistically significant differences were observed between the serine-mutants Vpu studied 191 
(Fig. 5b).  192 
193 
Discussion 194 
Despite the extensive knowledge about HIV molecular epidemiology, studies on HIV 195 
replication and pathogenesis among non-B isolates are still scarce. However, some clear 196 
subtype-specific features have been reported (Abraha et al., 2009; Arien et al., 2005; Geuenich 197 
et al., 2009; Holguin et al., 2006; Ramirez de Arellano et al., 2006).  198 
It has been proposed that the fact that only HIV-1 strains from the M group express a fully 199 
functional Vpu protein may explain, at least in part, the global HIV/AIDS pandemic for the 200 
HIV-1 M group (Petit et al., 2011; Sauter et al., 2011; Sauter et al., 2009). Notably, among the 201 
51 CRFs described until now, just 4 of them exhibit a recombinant structure involving the Vpu 202 
coding sequence; of them, CRF02_AG and CRF12_BF are the most represented recombinant 203 
forms in the infected population (Hemelaar et al., 2011). This might reflect some not yet clear 204 
recombination restrictions at this region and the importance of the conservation/preservation of 205 
its function.  206 
In a previous study we found that a naturally occurring BF intersubtype recombinant Vpu has 207 
an improved in vitro capacity to enhance viral replication. In addition, it was observed that the 208 
recombination pattern of other numerous BF recombinant sequences is very similar to that 209 
observed in the CRF12_BF, first described in Argentina. In a comparative analysis between 210 
subtype B and BF recombinant Vpu amino acid sequences, major differences were found in the 211 
α-helix II and C-terminal domains. This protein region has been strongly associated to Vpu 212 
functions, therefore partial and full deletions of the cytoplasmic domain, affected negatively its  213 
capacity to down-modulate CD4 (Pacyniak et al., 2005) or to promote viral release (Dube et 214 
al., 2009).  215 
Taking this evidence into account, the aim of this work was to determine the relevance of α-216 
helix II on the functional changes observed for the BF recombinant Vpu. To achieve this, two 217 
chimeric proteins where the α-helix II were exchanged between NL4-3, and BF recombinant 218 
variants were generated and used to perform in vitro studies.  219 
Our results indicate that the replacement of α-helix II (B→F), resembling the structure of the 220 
naturally occurring recombinant variant, directly correlated with the enhancement of viral 221 
release, and with a moderate increase in BST-2 and CD4 down-modulation capacity. This 222 
observation evidences that the α-helix II participates actively in the Vpu viral release-223 
promoting activity. 224 
We also found that subtype F1 Vpu was relatively less efficient in reducing BST-2 cell surface 225 
expression levels than the subtype B and BF recombinant Vpu studied. Nevertheless, its 226 
capacity to promote viral release was slightly higher than that observed in the subtype B 227 
variant. 228 
Of note, the relative augmentation of viral production among the variants studied did not 229 
directly correlate with their capacity to down-modulate BST-2 from the cell surface. This 230 
discrepancy has been previously observed (Dube et al., 2010; Goffinet et al., 2010; Kuhl et al., 231 
2011; Mitchell et al., 2009; Miyagi et al., 2009; Nomaguchi et al., 2010) allowing to 232 
hypothesize that both activities may be relatively independent. In this regard, Schmidt et al 233 
(Schmidt et al., 2011) found that Vpu may interfere with both the BST-2 recycling from the 234 
cell surface and the anterograde transport of newly synthesized BST-2, without affecting its 235 
internalization rate, which leads to a reduction in its virion-tethering activity at cell surface. 236 
Thus, BST-2 intracellular subpopulations with different trafficking characteristics and/or 237 
susceptibility to Vpu may exist, and have a higher antiviral activity potential than molecules at 238 
cell surface, explaining the lack of a precise correlation among viral production and BST-2 cell 239 
surface expression. 240 
On the other hand, the motif (E/D)XXXL(V/M/I) within α-helix II, which is highly conserved 241 
among Vpu proteins from HIV-1 M group subtypes A, B, D, G and H, has been recently 242 
identified as required for efficient BST-2 down-modulation and enhancement of viral release 243 
(Kueck & Neil, 2012). Vpu variants used in this work display differences in the location and 244 
amino acid composition of this motif, i.e. E59XXXL63V in subtype B and (D/E)62XXXL66(A) in 245 
subtype F1 and BF recombinant, and as suggested by Kuek and Neil (Kueck & Neil, 2012), 246 
such motifs may not be functionally equivalent.  247 
Proteasomal degradation of Vpu, which occurs through a β-TRCP complex independent 248 
pathway, has been shown to involve phosphorylation of a serine residue at position 61 249 
(Estrabaud et al., 2007). Mutation of S61 led to accumulation of Vpu within cells and 250 
augmentation of viral release. S61 is not present in CRF12_BF or related BF recombinant Vpu 251 
sequences, and only 6.6% of BF sequences had S64 (De Candia et al., 2010). These evidences 252 
prompted us to examine the effect of S61 and S64 on the BF recombinant Vpu function. Our 253 
results showed that both VpuBF E61S and the wild-type VpuBF E61 variants behaved 254 
similarly in terms of promoting viral release in a tetherin-expressing cell model. Nevertheless, 255 
we found a modest reduction in viral production when alanine residue at position 64 was 256 
replaced by serine. This change also correlated to a slight increase in the capacity of the 257 
VpuS64 variant to down-modulate BST-2. No changes in CD4 degradation were observed in 258 
VpuBF E61S or VpuBF A64S. Although the biological impact of these small differences 259 
remains to be established, these results suggest that regulation of Vpu degradation, and the 260 
relationship with the protein functions, is a complex process for which other steps may be 261 
required., regardless of the simple phosphorylation event,  262 
In summary, data presented here clearly show that structural modifications introduced by the 263 
intersubtype recombination in BF Vpu at the level of its α-helix II correlates with the 264 
previously observed augmentation in viral production, and with changes in its capacity to 265 
modulate the steady-state BST-2 and/or CD4 cell surface levels. Regarding the role of residues 266 
S61 and S64 in the BF Vpu function, we found that S64 but not S61 did affect the capacity of 267 
Vpu to down-modulate BST-2 and to promote viral release of the variant studied. To the best of 268 
our knowledge this is the first report obtained from other than a B subtype Vpu variant.  269 
Altogether, these findings shed more light on the molecular basis of the Vpu function, 270 
underscoring the power of recombination as a variability source during HIV-1 evolution.  271 
In an elegant report by Sato et al, it was shown that Vpu enhances the kinetics of cell-free virus 272 
propagation, especially during the initial phase of infection, which leads to a rapid systemic 273 
HIV-1 dissemination in vivo (Sato et al., 2012). Thus, if intersubtype recombination has the 274 
potential to generate structurally re-organized proteins with improved functions, such as the BF 275 
intersubtype recombinant Vpu, then viruses harbouring them may have biological advantages 276 
that play an important role in the successful spread of such HIV-1 recombinant variants.  277 
 278 
  279 
Methods 280 
 281 
Plasmids  282 
To perform the functional analysis, we generated vectors co-expressing Vpu and GFP from a 283 
single bicistronic RNA via an internal ribosome entry site (IRES). Briefly, vpu genes from 284 
HIV-1 subtype B molecular clone pNL4-3 (Adachi et al., 1986), subtype F1 molecular clone 285 
p93BR020.1 (Gao et al., 1998) and  pVpuBF vector previously described (De Candia et al., 286 
2010) were used as templates for a PCR designed to introduce the XbaI restriction site and a 287 
C-terminus 6xHis tag/MluI restriction site at 5’ and 3’ ends of the vpu coding sequence, 288 
respectively. Primers used for this reaction were:   289 
VpuB-XbaI (5´-CCTCTAGATAATGCAACCTATAATAG-3´),  290 
VpuB-6xHis-MluI (5´-CACGCGTTTAGTGATGGTGATGATGATGGCCGGATCCCAGATCATCAATATCC-3´),  291 
VpuF1-XbaI (5´- CCTCTAGATAATGTCAAATTTGTTAGC-3´),  292 
VpuF1-6xHis-MluI (5´- CACGCGTTTAGTGATGGTGATGATGATGGCCGGATCCCAGATTATTAATGTCC-3´),  293 
VpuBF  XbaI (5´-CCTCTAGATAATGCAATCTTTAG-3´) and 294 
VpuBF 6xHis-MluI (5´-CACGCGTTTAGTGATGGTGATGATGATGGCCGGATCCCAGAATATCAATATTC-3´) 295 
Nucleotide changes corresponding to restriction sites and sequence coding for the 6xHis Tag 296 
are underlined. Original Vpu stop codon was eliminated with the addition of the 297 
GSGHHHHHH amino acid sequence, and a new one was generated at the end of the tag 298 
(highlighted in bold). 299 
The amplicons obtained were first cloned into a commercial vector (pGEM T-easy, Promega) 300 
and then subcloned into the XbaI/MluI harboring bicistronic cytomegalovirus-based pCG 301 
expression vector co-expressing GFP (Lock et al., 1999; Mariani & Skowronski, 1993), 302 
generating expression vectors pCG-VpuB, pCG-VpuF1 and pCG-VpuBF. All mutagenesis 303 
reactions were performed using a highly processive DNA polymerase with proofreading 3’-5’ 304 
exonuclease activity (Platinum®PfxDNA Polymerase, Invitrogen). The Vpu expression 305 
vectors were then sequenced to assess vpu sequences integrity (Big Dye terminator kit and an 306 
ABI 3100 automated sequencer, Applied Biosystems Inc, Foster City CA). Nucleotide 307 
sequences from both strands were analyzed and manually adjusted using Sequencher 4.0.5 308 
software (Gene Codes Co, USA). 309 
For the construction of chimeric Vpu proteins, plasmids pCG-VpuB and pCG-VpuBF were 310 
digested with XbaI and BpiI, both, digestion products (vector and inserts containing coding 311 
sequences for the α-helix II and C-terminal domains), were gel purified and appropriate 312 
ligations were carried out using T4 DNA ligase (Promega). The resulting plasmids were 313 
named as pCG-VpuBF/B, where α-helix-II from CRF12_BF-like variant was replaced with 314 
that from NL4-3, and pCG-VpuB/F1, where α-helix-II from NL4-3 was replaced with that 315 
from the CRF12_BF-like variant (Fig. 1).  316 
Mutation of serine at position 61 or 64 in pCG-VpuBF, serine at position 64 in pCG-VpuB 317 
and alanine at position 61 in pCG-VpuB were introduced by site-directed mutagenesis. 318 
Briefly, PCR reaction was carried out by using the following set of forward primers, where 319 
codon substitutions are underlined:  320 
VpuB S61A (5`-GGAGAAGTAGCAGCACTTGTGG-3`) 321 
VpuB V64S (5´-GAAGTAGCAGCACTTTCGGAGATG-3´) 322 
VpuBF E61S (5`-GGATGCATCAGAATTGGCAGC-3`) 323 
VpuBF A64S (5´-GGATGCAGAAGAATTGTCAGC-3´) 324 
The amplicons were subcloned into a commercial vector (pGEM-T® easy vector, Promega), 325 
and then subcloned into pCG expression vector. The resulting vectors were sequenced to 326 
ensure that mutation was introduced and to assess any possible unwanted changes introduced 327 
during mutagenesis. The resulting plasmids were named as pCGVpuBF E61S, pCG-VpuBF 328 
A64S, pCG-VpuB S61A and pCG-VpuB V64S (Fig. 1). 329 
pNL4-3 U35 (Strebel et al., 1988), a derivate of pNL4-3 containing an insertion within the 330 
vpu ORF that causes a translational frame shift which results in a 35-amino acid truncated 331 
form of the Vpu protein, was used as negative control. 332 
 333 
Cells 334 
HeLa and HeLa CD4+ cells were used in this study. HeLa cells were cultured in DMEM 335 
medium (Gibco®) supplemented with 10% fetal bovine serum (FBS, Gibco®), 2 mM L-336 
glutamine (Gibco®) and penicillin/streptomycin (100 IU/ml and 100 µg/ml, respectively, 337 
Gibco®). HeLa CD4+ cells were cultured in the same medium plus 500 µg/ml G418. Cell lines 338 
were obtained through the AIDS Research and Reference Reagent Program. 339 
 340 
Viral release assay 341 
HeLa cells were co-transfected with 2 µg of HIV-1 proviral DNA (pNL4-3 U35) and 0.5 µg 342 
of each of the Vpu expression vectors. Co-transfection with 500 ng of pCG-GFP empty vector 343 
was set as negative control. Transient transfections were carried out using Lipofectamine2000 344 
(Invitrogen) following manufacturer’s instructions. Cell culture supernatants were collected 345 
24 and 48 hours post-transfection. HIV-1 p24 antigen levels were measured using a 346 
commercial ELISA kit (Murex, UK). 347 
 348 
Down-modulation of BST-2 and CD4 cell surface expression assays 349 
HeLa and HeLa CD4+ cells were transfected with 0.8 µg of the Vpu expression vectors 350 
separately using Lipofectamine2000 (Invitrogen) following manufacturer’s instructions. An 351 
empty vector was used as negative control. At 48 h post-transfection, Hela cells were 352 
harvested and incubated with the α-BST-2 primary antibody (obtained from the AIDS 353 
Research and Reference Reagent Program), washed twice with ice-cold 1% BSA-PBS and 354 
finally incubated with PE-conjugated anti-rabbit IgG secondary antibody (BD Bioscience) in 355 
1% BSA-PBS. Cells were washed twice with ice-cold 1% BSA-PBS and acquired in a BD 356 
FACSCanto flow cytometer. Data acquisition and analysis were performed using the BD 357 
FACSDiva software, determining mean fluorescence intensity (MFI) of PE for transfected 358 
cells (GFP positive) within the same well. 359 
HeLa CD4+ cell were stained with PE conjugated anti-CD4 monoclonal antibody (BD 360 
Bioscience) in 1% BSA-PBS. Cells were washed twice with ice-cold 1% BSA-PBS and 361 
analyzed as described above. 362 
 363 
Western blotting 364 
Vpu expression was assessed by transfecting HeLa cells with 4 µg of each pCG-Vpu 365 
expression vector using Lipofectamine2000 (Invitrogen) following manufacturer’s 366 
instructions. At 48 hour post-transfection, cells were harvested and lysed in RIPA buffer (1% 367 
NP-40, 0.5 % Na-DOC, 0.1 % SDS, 0.15 M NaCl; 50 mM Tris-HCl pH 7.4; 5 mM EDTA, 368 
protease inhibitor cocktail). Lysates were boiled at 95°C for 5 min, separated on 12.5% SDS-369 
PAGE gels under reducing conditions. After gel electrophoresis, proteins were transferred 370 
onto PVDF membranes. The expression of each Vpu variant in whole cellular lysates was 371 
analyzed by immunoblot using 1:2000 diluted mouse anti-6xHis (BD PharmingenTM) and 372 
secondary peroxidase labelled sheep anti-mouse antibody (Amersham Biosciences) at 1:2000 373 
for chemiluminescent detection (ECL, GE Healthcare). β-actin was used as loading control by 374 
immunoblot using 1:3000 diluted rabbit anti- β-actin (Abcam) and secondary peroxidase 375 
labelled goat anti-rabbit antibody (Abcam) at 1:2000 for chemiluminescent detection (ECL, 376 
GE Healthcare). Band intensity was quantified using the ImageJ software. 377 
 378 
Statistical analysis 379 
ANOVA with Tukey´s post-test (one-way ANOVA for comparison between groups) was 380 
used. P <0.01 was considered statistically significant. 381 
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 550 
  551 
Figure legends 552 
 553 
Figure 1 554 
Schematic representation of the HIV-1 Vpu expression vectors.  a) Amino acid alignment 555 
of Vpu proteins from HIV-1 subtype B, F, BF intersubtype recombinant and representations 556 
of the structural domains as well as the phosphorylation sites (asterisks) of Vpu. The 557 
substituted amino acids within α-helix II are represented in bold. b) Schematic representation 558 
of the Vpu chimeras. 559 
 560 
Figure 2 561 
Expression of B, F1, BF, chimeric and mutant Vpu proteins. Western blot of 6xHis-tagged 562 
Vpu in the pCG-Vpu-IRES-GFP vector showing expression of the various Vpu constructs in 563 
lysates of transfected HeLa cells. Empty vector was used as negative control, while β-actin 564 
was used as loading control. 565 
 566 
Figure 3 567 
Ability of vpu mutants to enhance viral release. a) Viral release induced by Vpu 568 
chimeras. b) Viral release induced by Vpu mutants. HeLa cells were co-transfected with 569 
pNL4-3 U35 and Vpu-GFP expressing vectors. Co-transfection with pCG-GFP empty vector 570 
was set as negative control. Viral release was evaluated by p24 antigen content in cell culture 571 
supernatants (ng/ml) 48 h post-transfection. Error bars indicate standard errors. Results are 572 
representative of two independent experiments. Statistical significance is represented as 573 
*p<0.01. 574 
 575 
Figure 4 576 
Vpu chimeras and mutants affect cell surface BST-2 down- modulation. a) BST-2 down-577 
modulation by Vpu chimeras. b) BST-2 down-modulation by Vpu mutants. HeLa cell 578 
cultures were transfected separately with pCG-Vpu-IRES-GFP expressing vectors. Empty 579 
vector was used as negative control. BST-2 surface expression represented as Mean 580 
Fluorescence Intensity (MFI) of GFP-positive cells. Bar graphs represent the means ± SD 581 
from three independent experiments. Histograms represent relative cell number vs. relative 582 
levels of BST-2 fluorescence intensity for GFP-positive cells. Black lines indicate the results 583 
of Vpu-GFP expression vector, and gray dotted line indicates the result of GFP empty control 584 
vector. Statistical significance is represented as *p<0.01. 585 
 586 
Figure 5 587 
Down- modulation of CD4 cell surface expression by Vpu chimeras and mutants. a) CD4 588 
down-modulation by Vpu chimeras. b) CD4 down-modulation by Vpu mutants.  HeLa 589 
CD4+ cell cultures were transfected separately with pCG-Vpu-IRES-GFP expressing vectors. 590 
Empty vector was used as negative control. CD4 surface expression represented as Mean 591 
Fluorescence Intensity (MFI) of GFP-positive cells. Bar graphs represent the means ± SD 592 
from three independent experiments. Histograms represent relative cell number vs. relative 593 
levels of CD4 fluorescence intensity for GFP-positive cells. Black lines indicate the results of 594 
Vpu-GFP expression vector, and gray dotted line indicates the result of GFP empty control 595 
vector. Statistical significance is represented as *p<0.01. 596 
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